1.Variants near CETP, MTTP and BUD13-ZPR1-APOA5 may be nominally associated with poor statin response among Filipinos.
Lourdes Ella G. Santos ; Jose B. Nevado, Jr. ; Eva Maria C. Cutiongco - de la Paz ; Lauro L. Abrahan IV ; Aimee Yvonne Criselle L. Aman ; Elmer Jasper B. Llanes ; Jose Donato A. Magno ; Deborah Ignacia D. Ona ; Felix Eduardo R. Punzalan ; Paul Ferdinand M. Reganit ; Richard Henry P. Tiongco II ; Jaime Alfonso M. Aherrera ; Charlene F. Agustin ; Adrian John P. Bejarin ; Rody G. Sy
Acta Medica Philippina 2022;56(10):23-31
Objective. Several studies showed that genetic factors affect responsiveness to statins among different populations. This study investigated the associations of candidate genetic variants with poor response to statins among Filipinos.
Methods. In this unmatched case-control study, dyslipidemic participants were grouped into statin responders and poor responders based on the degree of reduction in LDL-c from baseline. DNA from blood samples were genotyped and analyzed. The association of candidate variants with statin response was determined using chi-square and logistic regression analysis.
Results. We included 162 adults on statins (30 poor responders as cases, 132 good responders as controls). The following variants are nominally associated with poor response to statin among Filipinos at a per-comparison error rate of 0.05: rs173539 near CETP (OR=3.05, p=0.015), rs1800591 in MTTP (OR=3.07, p=0.021), and rs1558861 near the BUD13-ZPR1-APOA5 region (OR=5.08, p=0.004).
Conclusion. Genetic variants near CETP, MTTP and the BUD13-ZPR1-APOA5 region are associated with poor response to statins among Filipinos. Further study is recommended to test the external validity of the study in the general Filipino population.
Lipids ; Hydroxymethylglutaryl-CoA Reductase Inhibitors
2.A genetic polymorphism in GCKR may be associated with low high-density lipoprotein cholesterol phenotype among Filipinos: A case-control study.
Rody G. Sy ; Jose B. Nevado, Jr. ; Eddieson M. Gonzales ; Adrian John P. Bejarin ; Aimee Yvonne Criselle L. Aman ; Elmer Jasper B. Llanes ; Jose Donato A. Magno ; Deborah Ignacia D. Ona ; Felix Eduardo R. Punzalan ; Paul Ferdinand M. Reganit ; Lourdes Ella G. Santos ; Richard Henry P. Tiongco II ; Jaime Alfonso M. Aherrera ; Lauro L. Abrahan IV ; Charlene F. Agustin ; Eva Maria C. Cutiongco - de la Paz
Acta Medica Philippina 2022;56(10):49-56
Background. Low levels of high-density lipoprotein cholesterol (HDL-c) is a well-recognized risk factor in the development of cardiovascular diseases. Associated gene variants for low HDL-c have already been demonstrated in various populations. Such associations have yet to be established among Filipinos who reportedly have a much higher prevalence of low HDL-c levels compared to other races.
Objective. To determine the association of selected genetic variants and clinical factors with low HDL-c phenotype in Filipinos.
Methods. An age- and sex-matched case-control study was conducted among adult Filipino participants with serum HDL-c concentration less than 35 mg/dL (n=61) and those with HDL-c levels of more than 40 mg/dL (n=116). Genotyping was done using DNA obtained from blood samples. Candidate variants were correlated with the low HDL-c phenotype using chi-squared test and conditional logistic regression analysis.
Results. Twelve single nucleotide polymorphisms (SNPs) were associated with low HDL-c phenotype among Filipinos with univariate regression analysis. The variant rs1260326 of glucokinase regulator (GCKR) (CT genotype: adjusted OR=5.17; p-value=0.007; TT genotype: adjusted OR=6.28; p-value=0.027) remained associated with low HDL-c phenotype, together with hypertension and elevated body mass index, after multiple regression analysis.
Conclusion. The variant rs1260326 near GCKR is associated with low HDL-c phenotype among Filipinos. Its role in the expression of low HDL-c phenotype should be further investigated prior to the development of possible clinical applications.
Cardiovascular Diseases ; Dyslipidemias ; Genetics ; Polymorphism, Single Nucleotide
3.2023 Philippine Working Group Consensus Statement on renal denervation therapy for the management of hypertension
Raymond Oliva ; Deborah Ignacia D. Ona ; Lourdes Ella G. Santos ; Felix Eduardo Punzalan ; John David Tan ; Gilbert Villela ; Benjamin Balmores ; Krizia Camille Yap-Uy ; Roberta Maria Cawed-Mende ; Jose Nicholas Cruz
Philippine Journal of Cardiology 2024;52(1):12-18
BACKGROUND
Hypertension is the most common risk factor for cardiovascular disease in the Philippines. Despite the availability of antihypertensive medications that are effective, safe, and tolerated by Filipino patients, the numbers of uncontrolled hypertensives are still increasing. Several factors play in the poor control of blood pressure, particularly resistant hypertension and hyperactive sympathetic nervous system. Renal denervation therapy is a novel device that has been shown to lower blood pressure in patients with resistant and difficult-to-treat hypertension and is deemed safe in clinical trials. A Philippine Working Group composed of specialists in cardiology, hypertension, vascular surgery, and clinical epidemiology has come up with consensus statements in identifying patients who will benefit from the procedure. Locally, there is a need to have hypertension centers treating uncontrolled and resistant hypertension and offer renal denervation therapy to appropriate Filipino patients.
Blood Pressure